Assertio Holdings, Inc. (ASRT)
| Market Cap | 151.47M +156.3% |
| Revenue (ttm) | 102.16M -14.2% |
| Net Income | -35.69M |
| EPS | -5.56 |
| Shares Out | 6.46M |
| PE Ratio | n/a |
| Forward PE | 33.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 284,852 |
| Open | 23.38 |
| Previous Close | 23.37 |
| Day's Range | 23.38 - 23.45 |
| 52-Week Range | 8.61 - 23.46 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 24.43 (+4.22%) |
| Earnings Date | May 8, 2026 |
About ASRT
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older;... [Read more]
Financial Performance
In 2025, Assertio Holdings's revenue was $118.71 million, a decrease of -5.00% compared to the previous year's $124.96 million. Losses were -$30.38 million, 40.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ASRT stock is "Hold." The 12-month stock price target is $24.43, which is an increase of 4.22% from the latest price.
News
Assertio to be acquired by Zydus Worldwide DMCC for $23.50 per share
Assertio (ASRT) Holdings announced that, following an engagement process outlined under the revised merger agreement with Garda Therapeutics, the Company’s Board of Directors approved a definitive agr...
Assertio price target raised to $23.50 from $21.80 at Lake Street
Lake Street raised the firm’s price target on Assertio (ASRT) to $23.50 from $21.80 and keeps a Hold rating on the shares after the company announced that its board terminated…
Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, following an engagement process outlined under the revised merger agreeme...
Assertio, Garda agree to delay launch of tender offer
Assertio (ASRT) Holdings has reached a mutual agreement with Garda Therapeutics to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May…
Assertio and Garda Mutually Agree to Delay Launch of Tender Offer
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”)...
Assertio Holdings Quarterly report: Q1 2026
Assertio Holdings has published its Q1 2026 quarterly earnings report on May 8, 2026.
Assertio, Garda agree to postpone commencement of tender offer
Assertio (ASRT) Holdings has reached a mutual agreement with Garda Therapeutics to postpone the commencement of the previously announced tender offer to acquire all outstanding shares of Assertio to M...
Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”)...
Assertio price target raised to $21.80 from $18 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Assertio (ASRT) to $21.80 from $18 and keeps a Neutral rating on the shares. The firm cites Garda Therapeutics’…
Garda amends agreement to acquire Assertio to $21.80 per share in cash
Assertio (ASRT) Holdings announced that, on May 1, 2026, Assertio and Garda Therapeutics entered into an Amended and Restated Agreement and Plan of Merger pursuant to which Garda has increased…
Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, on May 1, 2026, Assertio and Garda Therapeutics (“Garda”) entered into an...
Assertio, Garda mutually agree to extend tender offer deadline
Assertio (ASRT) Holdings announced that it has reached a mutual agreement with Garda Therapeutics, Inc. to extend the deadline to commence the previously announced tender offer to acquire all outstand...
Assertio and Garda Mutually Agree to Extend Tender Offer Deadline
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”)...
Assertio Provides Update on Garda Therapeutics Tender Process
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today provided an update that Garda Therapeutics, Inc. (“Garda”) intends to commence the tende...
Assertio downgraded to Hold from Buy at Maxim
Maxim analyst Naz Rahman downgraded Assertio (ASRT) to Hold from Buy after the company announced it will be acquired by Garda Therapeutics for $18 per share, or $125.1M in total,…
Assertio downgraded to Hold at Lake Street after takeover agreement
As previously reported, Lake Street downgraded Assertio (ASRT) to Hold from Buy with a price target of $18, down from $45, after the company announced it will be acquired by…
Assertio downgraded to Hold from Buy at Lake Street
Lake Street downgraded Assertio (ASRT) to Hold from Buy with an $18 price target
Assertio downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju downgraded Assertio (ASRT) to Neutral from Buy with a price target of $18, down from $35, after the company agreed to be acquired by Garda…
Assertio to be acquired by Garda for $18 per share in cash plus CVR
Assertio (ASRT) announced a definitive agreement to be acquired by Garda Therapeutics for $18 per share in cash, or a total cash consideration of $125.1M, plus a contingent value right.
Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sal...
Assertio Announces Agreement to be Acquired by Garda Therapeutics
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced a definitive agreement (the “Garda Agreement”) to be acquired by Garda Therape...
Assertio Holdings Proxy statement: Proxy filing
Assertio Holdings filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Assertio Holdings Earnings Call Transcript: Q4 2025
ROLVEDON remains the primary growth driver, with 2026 guidance reflecting normalized sales and margin expansion. Indocin faces expected declines from generic competition, while disciplined capital allocation and a robust oncology-focused commercial platform position the company for future growth.
Assertio Holdings Annual report: Q4 2025
Assertio Holdings has published its Q4 2025 annual report on March 16, 2026.
Assertio Holdings Earnings release: Q4 2025
Assertio Holdings released its Q4 2025 earnings on March 16, 2026, summarizing the period's financial results.